Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression

BACKGROUND: Chimeric antigen receptor (CAR) T cells have demonstrated high clinical response rates against hematological malignancies (e.g., CD19+ cancers) but have shown limited activity in patients with solid tumors. Recent work showed that precise insertion of a CAR at a defined locus improves tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Katherine P, Piscopo, Nicole J, Forsberg, Matthew H, Saraspe, Louise A, Das, Amritava, Russell, Brittany, Smerchansky, Madeline, Cappabianca, Dan, Shi, Lei, Shankar, Keerthana, Sarko, Lauren, Khajanchi, Namita, La Vonne Denne, Nina, Ramamurthy, Apoorva, Ali, Adeela, Lazzarotto, Cicera R, Tsai, Shengdar Q, Capitini, Christian M, Saha, Krishanu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454086/
https://www.ncbi.nlm.nih.gov/pubmed/36382633
http://dx.doi.org/10.1136/jitc-2021-004446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454086/
https://www.ncbi.nlm.nih.gov/pubmed/36382633
http://dx.doi.org/10.1136/jitc-2021-004446

Ejemplares similares